Myriad diversifies companion Dx portfolio with RBM purchase
This article was originally published in Clinica
Myriad Genetics is moving beyond oncology and into new disease areas with the planned acquisition of privately-held biomarker screening service provider Rules-Based Medicine (RBM).
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.